Arthur Hauenstein Email & Phone Number

South San Francisco, California, United States

Biophysical characterization of lysosome targeting chimeras (LYTACs).

Brisbane, California, United States

• Contributed to Infectious Disease and Vaccines (IDV) therapeutic pipeline, including proposing new targets and supporting existing programs as protein sciences subject matter expert (SME) in viral biochemistry group..
• Designed, expressed, and purified target proteins. Conducted target validation and MoA studies.
• Worked with 20+ member, global, cross-functional team (including one direct report) to develop hit-finding plans and orthogonal assays (FRET, SPR, AlphaLISA, HTRF). Completed DEL, AS-MS (small-molecule), mRNA-display.
• Identified 2 hit series with different inhibition mechanisms that have nM to sub-nM potency in binding and biochemical assays (manuscript in preparation).
• Communicated project milestones, status updates, and team recommendations to senior leadership and key stakeholders. o Supported multiple programs as a protein sciences SME within IDV
• Expressed and purified recombinant proteins of interest from insect and bacterial cell hosts enabling affinity screening and downstream assay development.

Natick, Massachusetts, United States

• Core member of seed-stage company founded by Hao Wu and Judy Lieberman (Boston Children's Hospital / Harvard Medical School). Collaborated on design and setup of laboratory, including CapEx purchasing and equipment.
• Conducted target validation and MoA studies.
• Conceptualized and performed focused, target-based screen (ADP-Glo assay, ~3K diverse small-molecule kinase library) including construct design, protein production, and tool finding.
• Developed orthogonal SPR, NF-kB luciferase reporter, Western Blot, and ELISA-based assays.
• Identified tool compound with low micromolar binding and biochemical activity.

Boston, Massachusetts, United States

• Program in Cellular and Molecular Medicine (PI: Hao Wu, Ph.D.)Studied the activation and assembly mechanisms of innate immune complexes.o Project 1: Investigated the binding of polyubiquitin chains to NEMO
• Developed in vitro synthesis and purification scheme to make distinct length K63-linked and M1-linked polyUb chains.
• Conducted SEC-MALS and SEC-SAXS on full-length NEMO.
• Identified regions of NEMO that allosterically regulate binding to M1-linked polyUb chains. Characterized NEMO binding preference for M1-linked over K63-linked polyUb chains.o Project 2: Characterized the effect of the.
• Conducted extensive protein engineering and mutational analysis of TIR-TIR interaction interfaces to disrupt/limit L265P-driven TIR oligomerization for structural studies.
• Performed in vitro reconstitution studies of TLR-MAL-MyD88 assembly on supported lipid bilayers.

San Diego, California, United States

Department of Chemistry and Biochemistry (PI: Tom Huxford, Ph.D.)Conducted Structural/Biochemical/Biophysical Studies to Elucidate the Activation Mechanism and Substrate Selectivity of the Human Inhibitor of kappa B Kinase 2/Beta (IKK2/B).o Developed novel protein constructs and optimized baculoviral insect cell expression, purification, and.

Doctor Of Philosophy (Phd), Biochemistry

Doctor Of Philosophy (Phd), Biochemistry